Dr. Tarik Moroy, Ph.D., FCAHS is Director of the Hematopoises and Cancer Research unit and Full Research Professor at the Montreal Clinical Research Institute/Institut de recherches cliniques de Montréal (IRCM). From 2006 to 2019, he was the President and Scientific Director (PDS) of the IRCM. From 2007-2021, he also held the Canada Research Chair (Tier 1) in Hematopoiesis and Immune Cell Differentiation. He is also Full Research Professor at the Université de Montréal and adjunct professor at McGill University. Prof. Dr. Möröy studied Biochemistry in Tübingen, Munich and Paris, where he worked on his dissertation at the Institut Pasteur on the link between hepatitis B virus infections and liver cancer. He received his degree (Dr. rer. nat.) at the Ludwig-Maximilians University in Munich in 1987. Between 1988 and 1990, he was a postdoctoral research fellow at Columbia University in New York before he returned to Germany in 1991 where he accepted a position as a junior group leader and later as associate Professor at the Philipps University of Marburg. In 1996, he was appointed full Professor and Institute Director for over 10 years at the University Hospital in Essen, Germany, before he came to Montreal in 2006. During his work, he has trained over 60 postdoctoral fellows and graduate and undergraduate students.
The IRCM is a non-profit organization that conducts basic and clinical research in addition to training high-level scientists in an innovative technological environment. With approximately 425 people, the Institute brings together more than 35 laboratories working in the fields of cancer, immunology, neuroscience, cardiovascular and metabolic diseases, systems biology, and medicinal chemistry. As IRCM’s President and Scientific Director, Prof. Dr. Moroy provided leadership for 36 principal investigators in biomedical research. He was responsible for strategic planning; recruitment of researchers and clinician scientists; the institute’s funding; university-, hospital- and government relations; training; public communications and education; operations of the IRCM clinic; and overseeing the total budget (40M$) of one of Canada’s leading biomedical research institutions. Under his management, the IRCM vastly expanded its technical core facilities services and created a new graduate program focused on translational research. In 2015/16 he started the two major initiatives at the IRCM: a new Research Centre on Rare and Genetic Diseases in Adults and a Biomarker Pipeline.
Prof. Moroy runs his own research group at the IRCM and has authored a total of over 300 publications, including 180 original articles and reviews in scientific journals (h=65, >13.500 citations), and over 160 contributions to scientific meetings and conferences. He attracted over 12M$ in funding for his research since 2006; in 2019 he was awarded 1.2M$ from a Canadian Venture Capital firm AmorChem, Inc. to develop a new type of anti-cancer drugs in collaboration with McGill University and Biotechnology companies in Germany and Canada. In 2014, he received a recognition award from the Leukemia and Lymphoma Society. He was also appointed “Honorary Guest Professor” by the Capital University in Beijing for his outstanding achievements in immunology in 2015. He was an active member of the M8 Alliance of the World Health Summit from 2013-2018 and co-organizer of the 2017 World Health Summit Regional Meeting in Montreal, Canada. He was elected to the Board of Directors of the Canadian Society for Molecular Biosciences in 2015 and became Vice President in 2017 and then President of this Society in 2018 and currently exerts the role of secretary general. He is a member of the Board of Directors of Research Canada since 2016 and its Chair as of June 2023. He has served on the College of Reviewers for the Canadian Institutes of Health Research from 2017-2022. Dr. Moroy has been elected Fellow of the Canadian Academy of Health Sciences in 2018 and has been solicited as a reviewer for the German Council of Sciences and Humanities (Wissenschaftsrat) in 2012 and in 2019. In 2019 Dr. Moroy received the “Médaille de mérite de l’IRCM” for outstanding services as President and Scientific Director of this institution for 13 years from 2006 to 2019. In 2020, the German Minister of Education and Research appointed Dr. Möröy as a member of the “Expert group for the Excellence Strategy” in Germany. In 2021, Prof. Dr. Möröy was appointed member of the scientific advisory committee of HémaQuébec, a non-profit organization that supplies blood and other biological products of human origin to hospitals for the Canadian province of Quebec.